Currently, monoclonal antibodies targeting the CXCL14/ACKR3 axis are in Phase I tumor clinical trials (NCT04857112), and our study provides a theoretical basis for expanding their indications to IPF. Here, CXCL14 is linked to idiopathic pulmonary fibrosis.